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Quadruple-Drug Induction Therapy in Combined Renal and Pancreatic 
Transplantation—OKT3 Versus ATG 
W.-D. Iiiner, J. Theodorakis, D. Abendroth, S. Schleibner, M. Stangl, R. Landgraf, and W. Land 
THE pancreatic allograft rejection remains a major problem in pancreas transplantation. Despite the 
introduction of cyclosporin and other new immunosup-
pressive drugs, the incidence of rejection episodes range 
from 30% to 80%.1,2 We present here our experience with 
quadruple-drug induction therapy consisting of CS, azathi-
oprine, 4'high** doses of steroids and antithymocyte glob-
ulin (ATG) or OKT3 for a short period of time. 
PATIENTS A N D M E T H O D S 
In a controlled prospective study (March 1988 to July 1989), 20 
diabetics were grafted simultaneously with a pancreas and a 
kidney. We used the occlusion technique in six patients and the 
bladder drainage in four patients in each group. Recipients' 
criteria and number of H L A mean mismatches in both groups 
were comparable. 
Immunosuppressive Protocol 
In 10 patients (group I) in addition to triple-drug therapy 
ATG in a dosage of 4 mg/kg body weight was used. In 
group II, OKT3 (5 mg/d) was added to the standard 
regimen. ATG and OKT3 were given for 10 days (Table 1). 
Antirejection Therapy 
The first rejection episode was treated with 250 mg meth-
ylprednisolone for 3 days. The second and third rejection 
crises were treated with ATG or OKT3 for 7 days. Patients 
that received ATG as induction therapy were treated with 
OKT3 and vice versa. 
Table 1. Quadruple-Drug Induction Therapy in Pancreatic 
Transplantation (ATG vs OKT3) 
Cyclosporin 
Azathioprine 
ATG 
or 
OKT3 
Steroids 
1 mg/kg body weight for 24 h per infusion (blood 
levels, 100 ng/mL), switch to oral medication 
as soon as possible (6-10 mg/kg body weight) 
1-2 mg/kg body weight/d 
4 mg/kg body weight for 10 d 
5 mg/d for 10 d 
500 mg intraoperatively, reduced to maintenance 
dose of 30 mg/d within 1 wk 
RESULTS 
In total a pancreatic allograft rejection was observed in 10 
of 20 patients (5 in each group). In both groups one 
pancreatic graft was lost due to an irreversible rejection. A 
second pancreatic graft loss for an unknown reason was 
observed in the OKT3-treated group (Table 2). 
Kidney graft rejection was observed in four patients in 
the ATG group and in five patients in the OKT3 group. All 
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Table 2. Pancreatic Graft Losses 
ATG OKT3 
Total 2 3 
Immunological failure 1 1 
Patient death* 1 1 
Unknown 1 
'None of the patients' death was due to the immunosuppressive protocol. 
kidney graft rejection episodes were reversible with antire-
jection therapy. 
Six of 20 patients showed a parallel rejection episode in 
both organs (three in each group). The rate of infection 
complications was 60% in the ATG group and 40% in the 
OKT3 group (one life-threatening event in each group). 
One patient death (arrosion bleeding) occurred in each 
group. 
Patient and kidney survival probability rate is 90% in 
both groups. Pancreas survival probability is 60% in the 
OKT3 group and 80% in the ATG group. The difference is 
not statistically significant (Fig 1). 
CONCLUSIONS 
1. Quadruple-drug induction therapy using ATG or OKT3 
provides an effective immunosuppression with excellent 
graft survival and function. 
2. In our study the use of the monoclonal antibody OKT3 
did not provide an advantage over the use of a polyclonal 
antithymocyte sera regarding rejection episodes. 
3. The infection rate was high, but did not differ in either 
group. 
4. The small number of patients in each group does not 
allow final conclusions as to whether or not monoclonal 
antisera are better than polyclonal antisera. Both sera 
are optimal for treatment of acute rejection episodes. 
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